23 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Jan 2027

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027 202820292030 2031 20322033203420352036203720382039204020412042204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Storage and Dispensing Devices for Administration of Oral Transmucosal Dosage Forms US 8,548,623

The most cited patent in this portfolio, cited by 96 later US patents, top 10% of utility patents granted in 2013 in our data. Protection runs to 2031.

Ends Aug 2031 · High confidence Also notable

Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain US 8,226,978

Cited by 57 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.

Ends Jan 2027 · Medium confidence Also notable

Nutritional Supplement for Use Under Physiologically Stressful Conditions US 7,901,710

The largest patent family in this portfolio, 5 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027.

Ends Jun 2027 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Dec 13, 2026

Which patents, and when each one lapses · Pro

Recent changes

2 terms have ended since Aug 16, 2026

What they patent

The 5 largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Small-Volume Oral Transmucosal Dosage Forms	11 in force	to Oct 2030
Storage and Dispensing Devices for Administration of Oral Transmucosal Dosage Forms	5 in force	to Aug 2031
Nutritional Supplement for Women	2 in force	to Oct 2028
Apparatus and Methods for Dispensing Oral Transmucosal Dosage Forms	1 in force	to Feb 2038
Sufentanil Solid Dosage Forms Comprising Oxygen Scavengers and Methods of Using the Same	1 in force	to Jul 2031

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 8,252,328	Bioadhesive Drug Formulations for Oral Transmucosal Delivery In force Ends no later than Jan 5, 2027 · Medium confidence	In force	Ends no later than Jan 5, 2027	Medium confidence
US 8,535,714	Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain In force Term ends Jan 5, 2027 · Medium confidence	In force	Term ends Jan 5, 2027	Medium confidence
US 9,320,710	Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain In force Term ends Jan 5, 2027 · High confidence	In force	Term ends Jan 5, 2027	High confidence
US 9,744,129	Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain In force Term ends Jan 5, 2027 · High confidence	In force	Term ends Jan 5, 2027	High confidence
US 10,245,228	Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain In force Term ends Jan 5, 2027 · High confidence	In force	Term ends Jan 5, 2027	High confidence
US 10,342,762	Small-Volume Oral Transmucosal Dosage Forms In force Ends no later than Jan 5, 2027 · Medium confidence	In force	Ends no later than Jan 5, 2027	Medium confidence
US 10,507,180	Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain In force Term ends Jan 5, 2027 · High confidence	In force	Term ends Jan 5, 2027	High confidence
US 8,226,978	Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain In force Term ends Jan 23, 2027 · Medium confidence	In force	Term ends Jan 23, 2027	Medium confidence
US 7,901,710	Nutritional Supplement for Use Under Physiologically Stressful Conditions In force Term ends Jun 6, 2027 · High confidence	In force	Term ends Jun 6, 2027	High confidence
US 8,252,329	Bioadhesive Drug Formulations for Oral Transmucosal Delivery In force Ends no later than Aug 23, 2027 · Medium confidence	In force	Ends no later than Aug 23, 2027	Medium confidence

10 of 23 patents shown.

Pro members see all 23.

Pro members: see all 23 patents

Also on record, not counted in the 23: 9 patents ended · 3 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Vertical Pharmaceuticals, LLC